title: Tyrosine Kinase Inhibitor as a new Therapy for Ischemic Stroke and other Neurologic Diseases: is there any Hope for a Better Outcome?
abstract: The relevance of tyrosine kinase inhibitors (TKIs) in the treatment of malignancies has been already defined. Aberrant activation of tyrosine kinase signaling pathways has been causally linked not only to cancers but also to other non-oncological diseases. This review concentrates on the novel plausible usage of this group of drugs in neurological disorders, such as ischemic brain stroke, subarachnoid hemorrhage, Alzheimer's disease, multiple sclerosis. The drugs considered here are representatives of both receptor and non-receptor TKIs. Among them imatinib and masitinib have the broadest spectrum of therapeutic usage. Both drugs are effective in ischemic brain stroke and multiple sclerosis, but only imatinib produces a therapeutic effect in subarachnoid hemorrhage. Masitinib and dasatinib reduce the symptoms of Alzheimer's disease. In the case of multiple sclerosis several TKIs are useful, including apart from imatinib and masitinib, also sunitinib, sorafenib, lestaurtinib. Furthermore, the possible molecular targets for the drugs are described in connection with the underlying pathophysiological mechanisms in the diseases in question. The most frequent target for the TKIs is PDGFR which plays a pivotal role particularly in ischemic brain stroke and subarachnoid hemorrhage. The collected data indicates that TKIs are very promising candidates for new therapeutic interventions in neurological diseases.
authors.forename: Iwona
authors.initials: I
authors.lastname: Gągało
authors.forename: Izabela
authors.initials: I
authors.lastname: Rusiecka
authors.affiliation: Department of Pharmacology, Medical University of Gdansk, Debowa 23, 80-204, Gdansk, Poland. ikocic@gumed.edu.pl.
authors.forename: Ivan
authors.initials: I
authors.lastname: Kocić
mesh_terms: D000818:Animals; D002545:Brain Ischemia / Q000188:drug therapy* / Q000201:enzymology; D006801:Humans; D018696:Neuroprotective Agents / Q000494:pharmacology / Q000627:therapeutic use*; D047428:Protein Kinase Inhibitors / Q000494:pharmacology / Q000627:therapeutic use*; D011505:Protein-Tyrosine Kinases / Q000037:antagonists & inhibitors* / Q000378:metabolism; D020521:Stroke / Q000188:drug therapy* / Q000201:enzymology
chemical_list: D018696:Neuroprotective Agents; D047428:Protein Kinase Inhibitors; D011505:Protein-Tyrosine Kinases